Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 232

1.

Independent Validation of a Diagnostic Noninvasive 3-MicroRNA Ratio Model (uCaP) for Prostate Cancer in Cell-Free Urine.

Fredsøe J, Rasmussen AKI, Laursen EB, Cai Y, Howard KA, Pedersen BG, Borre M, Mouritzen P, Òrntoft T, Sørensen KD.

Clin Chem. 2019 Feb 6. pii: clinchem.2018.296681. doi: 10.1373/clinchem.2018.296681. [Epub ahead of print]

PMID:
30728149
2.

Clinical evaluation and treatment of chronic bowel symptoms following cancer in the colon and pelvic organs.

Larsen HM, Borre M, Christensen P, Mohr Drewes A, Laurberg S, Krogh K, Fassov J.

Acta Oncol. 2019 Jan 30:1-6. doi: 10.1080/0284186X.2018.1562211. [Epub ahead of print]

PMID:
30698052
3.

Quantitative tumor perfusion imaging with 82Rubidium-PET/CT in prostate cancer - analytical and clinical validation.

Jochumsen MR, Tolbod LP, Pedersen BG, Nielsen MM, Høyer S, Frøkiær J, Borre M, Bouchelouche K, Sorensen J.

J Nucl Med. 2019 Jan 25. pii: jnumed.118.219188. doi: 10.2967/jnumed.118.219188. [Epub ahead of print]

PMID:
30683762
4.

Author Correction: Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci.

Schumacher FR, Olama AAA, Berndt SI, Benlloch S, Ahmed M, Saunders EJ, Dadaev T, Leongamornlert D, Anokian E, Cieza-Borrella C, Goh C, Brook MN, Sheng X, Fachal L, Dennis J, Tyrer J, Muir K, Lophatananon A, Stevens VL, Gapstur SM, Carter BD, Tangen CM, Goodman PJ, Thompson IM Jr, Batra J, Chambers S, Moya L, Clements J, Horvath L, Tilley W, Risbridger GP, Gronberg H, Aly M, Nordström T, Pharoah P, Pashayan N, Schleutker J, Tammela TLJ, Sipeky C, Auvinen A, Albanes D, Weinstein S, Wolk A, Håkansson N, West CML, Dunning AM, Burnet N, Mucci LA, Giovannucci E, Andriole GL, Cussenot O, Cancel-Tassin G, Koutros S, Beane Freeman LE, Sorensen KD, Orntoft TF, Borre M, Maehle L, Grindedal EM, Neal DE, Donovan JL, Hamdy FC, Martin RM, Travis RC, Key TJ, Hamilton RJ, Fleshner NE, Finelli A, Ingles SA, Stern MC, Rosenstein BS, Kerns SL, Ostrer H, Lu YJ, Zhang HW, Feng N, Mao X, Guo X, Wang G, Sun Z, Giles GG, Southey MC, MacInnis RJ, FitzGerald LM, Kibel AS, Drake BF, Vega A, Gómez-Caamaño A, Szulkin R, Eklund M, Kogevinas M, Llorca J, Castaño-Vinyals G, Penney KL, Stampfer M, Park JY, Sellers TA, Lin HY, Stanford JL, Cybulski C, Wokolorczyk D, Lubinski J, Ostrander EA, Geybels MS, Nordestgaard BG, Nielsen SF, Weischer M, Bisbjerg R, Røder MA, Iversen P, Brenner H, Cuk K, Holleczek B, Maier C, Luedeke M, Schnoeller T, Kim J, Logothetis CJ, John EM, Teixeira MR, Paulo P, Cardoso M, Neuhausen SL, Steele L, Ding YC, De Ruyck K, De Meerleer G, Ost P, Razack A, Lim J, Teo SH, Lin DW, Newcomb LF, Lessel D, Gamulin M, Kulis T, Kaneva R, Usmani N, Singhal S, Slavov C, Mitev V, Parliament M, Claessens F, Joniau S, Van den Broeck T, Larkin S, Townsend PA, Aukim-Hastie C, Gago-Dominguez M, Castelao JE, Martinez ME, Roobol MJ, Jenster G, van Schaik RHN, Menegaux F, Truong T, Koudou YA, Xu J, Khaw KT, Cannon-Albright L, Pandha H, Michael A, Thibodeau SN, McDonnell SK, Schaid DJ, Lindstrom S, Turman C, Ma J, Hunter DJ, Riboli E, Siddiq A, Canzian F, Kolonel LN, Le Marchand L, Hoover RN, Machiela MJ, Cui Z, Kraft P, Amos CI, Conti DV, Easton DF, Wiklund F, Chanock SJ, Henderson BE, Kote-Jarai Z, Haiman CA, Eeles RA; Profile Study; Australian Prostate Cancer BioResource (APCB); IMPACT Study; Canary PASS Investigators; Breast and Prostate Cancer Cohort Consortium (BPC3); PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium; Cancer of the Prostate in Sweden (CAPS); Prostate Cancer Genome-wide Association Study of Uncommon Susceptibility Loci (PEGASUS); Genetic Associations and Mechanisms in Oncology (GAME-ON)/Elucidating Loci Involved in Prostate Cancer Susceptibility (ELLIPSE) Consortium.

Nat Genet. 2019 Feb;51(2):363. doi: 10.1038/s41588-018-0330-6.

PMID:
30622367
5.

Football Compared with Usual Care in Men with Prostate Cancer (FC Prostate Community Trial): A Pragmatic Multicentre Randomized Controlled Trial.

Bjerre ED, Brasso K, Jørgensen AB, Petersen TH, Eriksen AR, Tolver A, Christensen JF, Poulsen MH, Madsen SS, Østergren PB, Borre M, Krustrup P, Johansen C, Rørth M, Midtgaard J.

Sports Med. 2019 Jan;49(1):145-158. doi: 10.1007/s40279-018-1031-0.

PMID:
30506427
6.

Non-invasive quantification of tumor blood flow in prostate cancer using 15O-H2O PET/CT.

Tolbod LP, Nielsen MM, Pedersen BG, Høyer S, Harms HJ, Borre M, Borghammer P, Bouchelouche K, Frøkiær J, Sørensen J.

Am J Nucl Med Mol Imaging. 2018 Oct 20;8(5):292-302. eCollection 2018.

7.

Exploring the transcriptome of hormone-naive multifocal prostate cancer and matched lymph node metastases.

Schmidt L, Møller M, Haldrup C, Strand SH, Vang S, Hedegaard J, Høyer S, Borre M, Ørntoft T, Sørensen KD.

Br J Cancer. 2018 Dec;119(12):1527-1537. doi: 10.1038/s41416-018-0321-5. Epub 2018 Nov 19.

PMID:
30449885
8.

[Prostate cancer - screening and early detection].

Borre M.

Ugeskr Laeger. 2018 Nov 12;180(46). pii: V06180418. Danish.

PMID:
30417812
9.

An iso-osmolar oral supplement increases natriuresis and does not increase stomal output in patients with an ileostomy: A randomised, double-blinded, active comparator, crossover intervention study.

Rud C, Pedersen AKN, Wilkens TL, Borre M, Andersen JR, Moeller HB, Dahlerup JF, Hvas CL.

Clin Nutr. 2018 Oct 24. pii: S0261-5614(18)32485-3. doi: 10.1016/j.clnu.2018.10.014. [Epub ahead of print]

PMID:
30396772
10.

Heterozygous loss-of-function variants of MEIS2 cause a triad of palatal defects, congenital heart defects, and intellectual disability.

Verheije R, Kupchik GS, Isidor B, Kroes HY, Lynch SA, Hawkes L, Hempel M, Gelb BD, Ghoumid J, D'Amours G, Chandler K, Dubourg C, Loddo S, Tümer Z, Shaw-Smith C, Nizon M, Shevell M, Van Hoof E, Anyane-Yeboa K, Cerbone G, Clayton-Smith J, Cogné B, Corre P, Corveleyn A, De Borre M, Hjortshøj TD, Fradin M, Gewillig M, Goldmuntz E, Hens G, Lemyre E, Journel H, Kini U, Kortüm F, Le Caignec C, Novelli A, Odent S, Petit F, Revah-Politi A, Stong N, Strom TM, van Binsbergen E; DDD study, Devriendt K, Breckpot J.

Eur J Hum Genet. 2019 Feb;27(2):278-290. doi: 10.1038/s41431-018-0281-5. Epub 2018 Oct 5.

PMID:
30291340
11.

Active Surveillance for Localized Prostate Cancer: Nationwide Observational Study.

Thomsen FB, Jakobsen H, Langkilde NC, Borre M, Jakobsen EB, Frey A, Lund L, Lunden D, Dahl C, Helgstrand JT, Brasso K.

J Urol. 2019 Mar;201(3):520-527. doi: 10.1016/j.juro.2018.09.045.

PMID:
30240689
12.

Regional variation in surgery for pancreatic cancer in Denmark 2011-2015.

Wennervaldt K, Kejs AM, Lipczak H, Bartels P, Borre M, Fristrup CW, Kehlet H.

Dan Med J. 2018 Sep;65(9). pii: A5503.

PMID:
30187862
13.

Robot-assisted laparoscopic cystectomy with intracorporeal urinary diversion vs. open mini-laparotomy cystectomy: evaluation of surgical inflammatory response and immunosuppressive ability of CO2-pneumoperitoneum in an experimental porcine study.

Kingo PS, Rasmussen TM, Jakobsen LK, Palmfeldt J, Nørregaard R, Borre M, Jensen JB.

Scand J Urol. 2018 Aug;52(4):249-255. doi: 10.1080/21681805.2018.1484508. Epub 2018 Sep 6.

PMID:
30185097
14.

Dysregulation and prognostic potential of 5-methylcytosine (5mC), 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), and 5-carboxylcytosine (5caC) levels in prostate cancer.

Storebjerg TM, Strand SH, Høyer S, Lynnerup AS, Borre M, Ørntoft TF, Sørensen KD.

Clin Epigenetics. 2018 Aug 7;10(1):105. doi: 10.1186/s13148-018-0540-x.

15.

Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment.

Attard G, Borre M, Gurney H, Loriot Y, Andresen-Daniil C, Kalleda R, Pham T, Taplin ME; PLATO collaborators.

J Clin Oncol. 2018 Sep 1;36(25):2639-2646. doi: 10.1200/JCO.2018.77.9827. Epub 2018 Jul 20.

16.

Scandinavian Prostate Cancer Patients' Sexual Problems and Satisfaction With Their Sex Life Following Anti-Cancer Treatment.

Martin Hald G, Dahl Pind M, Borre M, Lange T.

Sex Med. 2018 Sep;6(3):210-216. doi: 10.1016/j.esxm.2018.06.002. Epub 2018 Jul 13.

17.

Training and validation of a novel 4-miRNA ratio model (MiCaP) for prediction of postoperative outcome in prostate cancer patients.

Schmidt L, Fredsøe J, Kristensen H, Strand SH, Rasmussen A, Høyer S, Borre M, Mouritzen P, Ørntoft T, Sørensen KD.

Ann Oncol. 2018 Sep 1;29(9):2003-2009. doi: 10.1093/annonc/mdy243.

18.

Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants.

Dadaev T, Saunders EJ, Newcombe PJ, Anokian E, Leongamornlert DA, Brook MN, Cieza-Borrella C, Mijuskovic M, Wakerell S, Olama AAA, Schumacher FR, Berndt SI, Benlloch S, Ahmed M, Goh C, Sheng X, Zhang Z, Muir K, Govindasami K, Lophatananon A, Stevens VL, Gapstur SM, Carter BD, Tangen CM, Goodman P, Thompson IM Jr, Batra J, Chambers S, Moya L, Clements J, Horvath L, Tilley W, Risbridger G, Gronberg H, Aly M, Nordström T, Pharoah P, Pashayan N, Schleutker J, Tammela TLJ, Sipeky C, Auvinen A, Albanes D, Weinstein S, Wolk A, Hakansson N, West C, Dunning AM, Burnet N, Mucci L, Giovannucci E, Andriole G, Cussenot O, Cancel-Tassin G, Koutros S, Freeman LEB, Sorensen KD, Orntoft TF, Borre M, Maehle L, Grindedal EM, Neal DE, Donovan JL, Hamdy FC, Martin RM, Travis RC, Key TJ, Hamilton RJ, Fleshner NE, Finelli A, Ingles SA, Stern MC, Rosenstein B, Kerns S, Ostrer H, Lu YJ, Zhang HW, Feng N, Mao X, Guo X, Wang G, Sun Z, Giles GG, Southey MC, MacInnis RJ, FitzGerald LM, Kibel AS, Drake BF, Vega A, Gómez-Caamaño A, Fachal L, Szulkin R, Eklund M, Kogevinas M, Llorca J, Castaño-Vinyals G, Penney KL, Stampfer M, Park JY, Sellers TA, Lin HY, Stanford JL, Cybulski C, Wokolorczyk D, Lubinski J, Ostrander EA, Geybels MS, Nordestgaard BG, Nielsen SF, Weisher M, Bisbjerg R, Røder MA, Iversen P, Brenner H, Cuk K, Holleczek B, Maier C, Luedeke M, Schnoeller T, Kim J, Logothetis CJ, John EM, Teixeira MR, Paulo P, Cardoso M, Neuhausen SL, Steele L, Ding YC, De Ruyck K, De Meerleer G, Ost P, Razack A, Lim J, Teo SH, Lin DW, Newcomb LF, Lessel D, Gamulin M, Kulis T, Kaneva R, Usmani N, Slavov C, Mitev V, Parliament M, Singhal S, Claessens F, Joniau S, Van den Broeck T, Larkin S, Townsend PA, Aukim-Hastie C, Gago-Dominguez M, Castelao JE, Martinez ME, Roobol MJ, Jenster G, van Schaik RHN, Menegaux F, Truong T, Koudou YA, Xu J, Khaw KT, Cannon-Albright L, Pandha H, Michael A, Kierzek A, Thibodeau SN, McDonnell SK, Schaid DJ, Lindstrom S, Turman C, Ma J, Hunter DJ, Riboli E, Siddiq A, Canzian F, Kolonel LN, Le Marchand L, Hoover RN, Machiela MJ, Kraft P; PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium, Freedman M, Wiklund F, Chanock S, Henderson BE, Easton DF, Haiman CA, Eeles RA, Conti DV, Kote-Jarai Z.

Nat Commun. 2018 Jun 11;9(1):2256. doi: 10.1038/s41467-018-04109-8.

19.

Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci.

Schumacher FR, Al Olama AA, Berndt SI, Benlloch S, Ahmed M, Saunders EJ, Dadaev T, Leongamornlert D, Anokian E, Cieza-Borrella C, Goh C, Brook MN, Sheng X, Fachal L, Dennis J, Tyrer J, Muir K, Lophatananon A, Stevens VL, Gapstur SM, Carter BD, Tangen CM, Goodman PJ, Thompson IM Jr, Batra J, Chambers S, Moya L, Clements J, Horvath L, Tilley W, Risbridger GP, Gronberg H, Aly M, Nordström T, Pharoah P, Pashayan N, Schleutker J, Tammela TLJ, Sipeky C, Auvinen A, Albanes D, Weinstein S, Wolk A, Håkansson N, West CML, Dunning AM, Burnet N, Mucci LA, Giovannucci E, Andriole GL, Cussenot O, Cancel-Tassin G, Koutros S, Beane Freeman LE, Sorensen KD, Orntoft TF, Borre M, Maehle L, Grindedal EM, Neal DE, Donovan JL, Hamdy FC, Martin RM, Travis RC, Key TJ, Hamilton RJ, Fleshner NE, Finelli A, Ingles SA, Stern MC, Rosenstein BS, Kerns SL, Ostrer H, Lu YJ, Zhang HW, Feng N, Mao X, Guo X, Wang G, Sun Z, Giles GG, Southey MC, MacInnis RJ, FitzGerald LM, Kibel AS, Drake BF, Vega A, Gómez-Caamaño A, Szulkin R, Eklund M, Kogevinas M, Llorca J, Castaño-Vinyals G, Penney KL, Stampfer M, Park JY, Sellers TA, Lin HY, Stanford JL, Cybulski C, Wokolorczyk D, Lubinski J, Ostrander EA, Geybels MS, Nordestgaard BG, Nielsen SF, Weischer M, Bisbjerg R, Røder MA, Iversen P, Brenner H, Cuk K, Holleczek B, Maier C, Luedeke M, Schnoeller T, Kim J, Logothetis CJ, John EM, Teixeira MR, Paulo P, Cardoso M, Neuhausen SL, Steele L, Ding YC, De Ruyck K, De Meerleer G, Ost P, Razack A, Lim J, Teo SH, Lin DW, Newcomb LF, Lessel D, Gamulin M, Kulis T, Kaneva R, Usmani N, Singhal S, Slavov C, Mitev V, Parliament M, Claessens F, Joniau S, Van den Broeck T, Larkin S, Townsend PA, Aukim-Hastie C, Gago-Dominguez M, Castelao JE, Martinez ME, Roobol MJ, Jenster G, van Schaik RHN, Menegaux F, Truong T, Koudou YA, Xu J, Khaw KT, Cannon-Albright L, Pandha H, Michael A, Thibodeau SN, McDonnell SK, Schaid DJ, Lindstrom S, Turman C, Ma J, Hunter DJ, Riboli E, Siddiq A, Canzian F, Kolonel LN, Le Marchand L, Hoover RN, Machiela MJ, Cui Z, Kraft P, Amos CI, Conti DV, Easton DF, Wiklund F, Chanock SJ, Henderson BE, Kote-Jarai Z, Haiman CA, Eeles RA; Profile Study; Australian Prostate Cancer BioResource (APCB); IMPACT Study; Canary PASS Investigators; Breast and Prostate Cancer Cohort Consortium (BPC3); PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium; Cancer of the Prostate in Sweden (CAPS); Prostate Cancer Genome-wide Association Study of Uncommon Susceptibility Loci (PEGASUS); Genetic Associations and Mechanisms in Oncology (GAME-ON)/Elucidating Loci Involved in Prostate Cancer Susceptibility (ELLIPSE) Consortium.

Nat Genet. 2018 Jul;50(7):928-936. doi: 10.1038/s41588-018-0142-8. Epub 2018 Jun 11. Erratum in: Nat Genet. 2019 Feb;51(2):363.

PMID:
29892016
20.

Biomarker potential of ST6GALNAC3 and ZNF660 promoter hypermethylation in prostate cancer tissue and liquid biopsies.

Haldrup C, Pedersen AL, Øgaard N, Strand SH, Høyer S, Borre M, Ørntoft TF, Sørensen KD.

Mol Oncol. 2018 Apr;12(4):545-560. doi: 10.1002/1878-0261.12183. Epub 2018 Mar 13.

21.

Perceptions about screening for prostate cancer using genetic lifetime risk assessment: a qualitative study.

Kirkegaard P, Edwards A, Nielsen TLO, Ørntoft TF, Sørensen KD, Borre M, Bro F.

BMC Fam Pract. 2018 Feb 17;19(1):32. doi: 10.1186/s12875-018-0717-6.

22.

Soluble HER3 predicts survival in bladder cancer patients.

Memon AA, Gilliver SC, Borre M, Sundquist J, Sundquist K, Nexo E, Sorensen BS.

Oncol Lett. 2018 Feb;15(2):1783-1788. doi: 10.3892/ol.2017.7470. Epub 2017 Nov 22.

23.

Docetaxel Versus Surveillance After Radical Prostatectomy for High-risk Prostate Cancer: Results from the Prospective Randomised, Open-label Phase 3 Scandinavian Prostate Cancer Group 12 Trial.

Ahlgren GM, Flodgren P, Tammela TLJ, Kellokumpu-Lehtinen P, Borre M, Angelsen A, Iversen JR, Sverrisdottir A, Jonsson E, Sengelov L; Investigators of the Scandinavian Prostate Cancer Study Number 12.

Eur Urol. 2018 Jun;73(6):870-876. doi: 10.1016/j.eururo.2018.01.012. Epub 2018 Feb 1.

PMID:
29395502
24.

Nutritional status and nutritional risk in patients with neuroendocrine tumors.

Borre M, Dam GA, Knudsen AW, Grønbaek H.

Scand J Gastroenterol. 2018 Mar;53(3):284-292. doi: 10.1080/00365521.2018.1430848. Epub 2018 Jan 26.

PMID:
29373941
25.

Reply to M. Nayan et al.

Larsen SB, Dehlendorff C, Skriver C, Dalton SO, Jespersen CG, Borre M, Brasso K, Nørgaard M, Johansen C, Sørensen HT, Hallas J, Friis S.

J Clin Oncol. 2018 Feb 20;36(6):629-630. doi: 10.1200/JCO.2017.76.7186. Epub 2017 Dec 20. No abstract available.

PMID:
29261443
26.

Multi-parametric magnetic resonance imaging monitoring patients in active surveillance for prostate cancer: a prospective cohort study.

Elkjær MC, Andersen MH, Høyer S, Pedersen BG, Borre M.

Scand J Urol. 2018 Feb;52(1):8-13. doi: 10.1080/21681805.2017.1409265. Epub 2017 Dec 7.

PMID:
29212392
27.

Comprehensive Evaluation of TFF3 Promoter Hypomethylation and Molecular Biomarker Potential for Prostate Cancer Diagnosis and Prognosis.

Nørgaard M, Haldrup C, Storebjerg TM, Vestergaard EM, Wild PJ, Høyer S, Borre M, Ørntoft TF, Sørensen KD.

Int J Mol Sci. 2017 Sep 20;18(9). pii: E2017. doi: 10.3390/ijms18092017.

28.

[Nutrition and dietary supplement in chronic inflammatory bowel diesease].

Hvas CL, Borre M, Fassov JL.

Ugeskr Laeger. 2017 Jul 31;179(31). pii: V12160870. Review. Danish.

PMID:
28869011
29.

Long-Term Antitumor Activity and Safety of Enzalutamide Monotherapy in Hormone Naïve Prostate Cancer: 3-Year Open Label Followup Results.

Tombal B, Borre M, Rathenborg P, Werbrouck P, Van Poppel H, Heidenreich A, Iversen P, Braeckman J, Heracek J, Baron B, Krivoshik A, Hirmand M, Smith MR.

J Urol. 2018 Feb;199(2):459-464. doi: 10.1016/j.juro.2017.08.103. Epub 2017 Sep 1.

PMID:
28867562
30.

Postdiagnosis Statin Use and Mortality in Danish Patients With Prostate Cancer.

Larsen SB, Dehlendorff C, Skriver C, Dalton SO, Jespersen CG, Borre M, Brasso K, Nørgaard M, Johansen C, Sørensen HT, Hallas J, Friis S.

J Clin Oncol. 2017 Oct 10;35(29):3290-3297. doi: 10.1200/JCO.2016.71.8981. Epub 2017 Aug 14.

PMID:
28806117
31.

[The bear is sleeping, the bear is sleeping...].

Borre M.

Ugeskr Laeger. 2017 Jul 24;179(30). pii: V69094. Danish. No abstract available.

PMID:
28789763
32.

Diagnostic and Prognostic MicroRNA Biomarkers for Prostate Cancer in Cell-free Urine.

Fredsøe J, Rasmussen AKI, Thomsen AR, Mouritzen P, Høyer S, Borre M, Ørntoft TF, Sørensen KD.

Eur Urol Focus. 2018 Dec;4(6):825-833. doi: 10.1016/j.euf.2017.02.018. Epub 2017 Mar 9.

33.

Long-term urodynamic findings following radical prostatectomy and salvage radiotherapy.

Ervandian M, Djurhuus JC, Høyer M, Graugaard-Jensen C, Borre M.

Scand J Urol. 2018 Feb;52(1):20-26. doi: 10.1080/21681805.2017.1354067. Epub 2017 Jul 27.

PMID:
28748746
34.

Late urinary morbidity and quality of life after radical prostatectomy and salvage radiotherapy for prostate cancer.

Ervandian M, Høyer M, Petersen SE, Sengeløv L, Hansen S, Kempel MM, Meidahl Petersen P, Borre M.

Scand J Urol. 2017 Dec;51(6):457-463. doi: 10.1080/21681805.2017.1354314. Epub 2017 Jul 27.

PMID:
28748716
35.

Prostate cancer: in-bore magnetic resonance guided biopsies at active surveillance inclusion improve selection of patients for active treatment.

Elkjær MC, Andersen MH, Høyer S, Pedersen BG, Borre M.

Acta Radiol. 2018 May;59(5):619-626. doi: 10.1177/0284185117723372. Epub 2017 Jul 26.

PMID:
28747132
36.
37.

Perioperative Systemic Inflammatory Response following Robot-Assisted Laparoscopic Cystectomy vs. Open Mini-Laparotomy Cystectomy: A Prospective Study.

Skjold Kingo P, Palmfeldt J, Nørregaard R, Borre M, Jensen JB.

Urol Int. 2017;99(4):436-445. doi: 10.1159/000478274. Epub 2017 Jul 1.

PMID:
28668947
38.

Branched-chain amino acids for people with hepatic encephalopathy.

Gluud LL, Dam G, Les I, Marchesini G, Borre M, Aagaard NK, Vilstrup H.

Cochrane Database Syst Rev. 2017 May 18;5:CD001939. doi: 10.1002/14651858.CD001939.pub4. Review.

PMID:
28518283
39.

[And there was light].

Borre M.

Ugeskr Laeger. 2017 May 1;179(18). pii: V69130. Danish. No abstract available.

PMID:
28473019
40.

A lifestyle intervention among elderly men on active surveillance for non-aggressive prostate cancer: a randomised feasibility study with whole-grain rye and exercise.

Eriksen AK, Hansen RD, Borre M, Larsen RG, Jensen JM, Overgaard K, Borre M, Kyrø C, Landberg R, Olsen A, Tjønneland A.

Trials. 2017 Jan 13;18(1):20. doi: 10.1186/s13063-016-1734-1.

41.

Heterogeneous patterns of DNA methylation-based field effects in histologically normal prostate tissue from cancer patients.

Møller M, Strand SH, Mundbjerg K, Liang G, Gill I, Haldrup C, Borre M, Høyer S, Ørntoft TF, Sørensen KD.

Sci Rep. 2017 Jan 13;7:40636. doi: 10.1038/srep40636.

42.

RHCG and TCAF1 promoter hypermethylation predicts biochemical recurrence in prostate cancer patients treated by radical prostatectomy.

Strand SH, Switnicki M, Moller M, Haldrup C, Storebjerg TM, Hedegaard J, Nordentoft I, Hoyer S, Borre M, Pedersen JS, Wild PJ, Park JY, Orntoft TF, Sorensen KD.

Oncotarget. 2017 Jan 24;8(4):5774-5788. doi: 10.18632/oncotarget.14391.

43.

The Danish Prostate Cancer Database.

Nguyen-Nielsen M, Høyer S, Friis S, Hansen S, Brasso K, Jakobsen EB, Moe M, Larsson H, Søgaard M, Nakano A, Borre M.

Clin Epidemiol. 2016 Oct 25;8:649-653. eCollection 2016. Review.

44.

Parkinson's disease and risk of prostate cancer: A Danish population-based case-control study, 1995-2010.

Jespersen CG, Nørgaard M, Borre M.

Cancer Epidemiol. 2016 Dec;45:157-161. doi: 10.1016/j.canep.2016.11.002. Epub 2016 Nov 10.

PMID:
27838564
45.

Diagnostic and Therapeutic Strategies for Prostate Cancer.

Nguyen-Nielsen M, Borre M.

Semin Nucl Med. 2016 Nov;46(6):484-490. doi: 10.1053/j.semnuclmed.2016.07.002. Epub 2016 Sep 3. Review.

PMID:
27825428
46.

Evaluation of robot-assisted laparoscopic versus open cystectomy and effect of carbon dioxide-pneumoperitoneum on histopathological findings in ureteroenteric anastomoses: results from an experimental randomized porcine study.

Kingo PS, Rasmussen TM, Nørregaard R, Borre M, Høyer S, Jensen JB.

Scand J Urol. 2017 Feb;51(1):50-56. doi: 10.1080/21681805.2016.1247294. Epub 2016 Nov 4.

PMID:
27809635
47.

Benzoxazinoids in Prostate Cancer Patients after a Rye-Intensive Diet: Methods and Initial Results.

Steffensen SK, Pedersen HA, Adhikari KB, Laursen BB, Jensen C, Høyer S, Borre M, Pedersen HH, Borre M, Edwards D, Fomsgaard IS.

J Agric Food Chem. 2016 Nov 2;64(43):8235-8245. Epub 2016 Oct 20.

PMID:
27718574
48.

HNF1B variants associate with promoter methylation and regulate gene networks activated in prostate and ovarian cancer.

Ross-Adams H, Ball S, Lawrenson K, Halim S, Russell R, Wells C, Strand SH, Ørntoft TF, Larson M, Armasu S, Massie CE, Asim M, Mortensen MM, Borre M, Woodfine K, Warren AY, Lamb AD, Kay J, Whitaker H, Ramos-Montoya A, Murrell A, Sørensen KD, Fridley BL, Goode EL, Gayther SA, Masters J, Neal DE, Mills IG.

Oncotarget. 2016 Nov 15;7(46):74734-74746. doi: 10.18632/oncotarget.12543.

49.

[The development of a generic guideline for multidisciplinary team conferences in Denmark].

Lajer H, Hillingsø J, Høyer S, Rasmussen TR, Hagemann-Madsen RH, Petersen LN, Dehn P, Borre M, Lundvall L.

Ugeskr Laeger. 2016 Sep 26;178(39). pii: V06160408. Danish.

PMID:
27697127
50.

Spatial and temporal clonal evolution during development of metastatic urothelial carcinoma.

Thomsen MB, Nordentoft I, Lamy P, Høyer S, Vang S, Hedegaard J, Borre M, Jensen JB, Ørntoft TF, Dyrskjøt L.

Mol Oncol. 2016 Nov;10(9):1450-1460. doi: 10.1016/j.molonc.2016.08.003. Epub 2016 Aug 17.

Supplemental Content

Support Center